针对性白血病对非正规PI3Kγ信号的依赖性
Qingyu Luo1, Evangeline G Raulston1, Miguel A Prado2,3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nature
|May 8, 2024
概括
这项研究揭示了急性白血病的新点:酸-3-激酶- (PI3Kγ) 和其途径. 抑制PI3Kγ在治疗白血病方面是有前途的,尤其是在与其他疗法相结合时.
科学领域:
- 癌症学
- 免疫学
- 分子生物学
背景情况:
- 已知酸-3-激酶- (PI3Kγ) 对固体癌症的抗瘤免疫力有影响.
- 在癌细胞,特别是白血病中,PI3Kγ的具体作用仍然很大程度上不明.
研究的目的:
- 研究PI3Kγ在急性白血病中的细胞内在功能.
- 确定PI3Kγ信号通路中的潜在治疗点,用于治疗白血病.
主要方法:
- 在各种急性白血病中使用全基因组CRISPR干扰查.
- 进行功能分析以了解PI3Kγ通路激活和下游影响.
- 这项研究将基因查与生物化学和细胞检测结合起来.
主要成果:
- 一部分急性白血病对PI3Kγ复合体具有依赖性,与PIK3R5激活和先天的炎症信号相关.
- PI3Kγ直接化p21 (RAC1) 激活激酶1 (PAK1),这是这种依赖的关键媒介.
- 通过影响PAK1脱,抑制PI3Kγ会影响线粒体的氧化化.
- 在激活PIK3R5的白血病中,PI3Kγ抑制剂eganelisib表现出有效性.
- 在临床前模型中,即使PIK3R5表达率低,eganelisib和cytarabine的联合治疗也改善了生存率.
结论:
- 在急性白血病中,PI3Kγ-PAK1信号表示可向的依赖性.
- 针对PI3Kγ,特别是以eganelisib,为白血病提供了潜在的治疗策略.
- 使用PI3Kγ抑制剂的组合疗法显示出增强的疗效,需要进行临床评估.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


